Abstract
Objectives Older adults with subjective cognitive decline (SCD) recruited from memory clinics have an increased risk of developing dementia and regularly experience reduced psychological well-being related to memory concerns and fear of dementia. Research on improving well-being in SCD is limited and lacks non-pharmacological approaches. We investigated whether mindfulness-based and health education interventions can enhance well-being in SCD.
Methods The SCD-Well trial (ClinicalTrials.gov: NCT03005652) randomised 147 older adults with SCD to an 8-week caring mindfulness-based approach for seniors (CMBAS) or an active comparator (health self-management programme [HSMP]). Well-being was assessed at baseline, post-intervention, and 6-month post-randomisation using the Psychological Well-being Scale (PWBS), the World Health Organisation’s Quality of Life (QoL) Assessment psychological subscale, and composites capturing meditation-based well-being dimensions of awareness, connection, and insight. Mixed effects models were used to assess between- and within-group differences in change.
Results CMBAS was superior to HSMP on changes in connection at post-intervention. Within both groups, PWBS total scores, psychological QoL, and composite scores did not increase. Exploratory analyses indicated increases in PWBS autonomy at post-intervention in both groups.
Conclusion Two non-pharmacological interventions were associated with only limited effects on psychological well-being in SCD. Longer intervention studies with waitlist/retest control groups are needed to assess if our findings reflect intervention brevity and/or minimal base rate changes in well-being.
Competing Interest Statement
GC has received research support from the EUs Horizon 2020 research and innovation programme (grant agreement number 667696), Inserm, Fondation dentreprise MMA des Entrepreneurs du Futur, Fondation Alzheimer, Programme Hospitalier de Recherche Clinique, Région Normandie, Association France Alzheimer et maladies apparentées and Fondation Vaincre Alzheimer (all to Inserm), and personal fees from Fondation dentreprise MMA des Entrepreneurs du Futur. All other authors have declared that no competing interests exist.
Clinical Trial
ClinicalTrials.gov: NCT03005652
Clinical Protocols
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296291/
Funding Statement
The SCD-Well Randomised Controlled Trial is part of the Medit-Ageing project funded through the European Union in Horizon 2020 programme related to the call PHC22 “Promoting mental well-being in the ageing population” and under grant agreement No667696. FC was supported by Fonds National de la Recherche Scientifique (FRS-FNRS, Belgium). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Written informed consent was obtained from all participants after the procedures had been explained to them and prior to participation. The multi-centre SCD-Well trial received ethics approval from the committees and regulatory agencies of all centres: London, UK (Queen Square Research Ethics Committee: n 17/LO/0056 and Health Research Authority National Health Service, IRAS project ID: 213008) Lyon, France (Comité de Protection des Personnes Sud-Est II Groupement Hospitalier Est: n 2016-30-1 and Agence Nationale de Sécurité du Médicament et des Produits de Santé: IDRCB 2016-A01298-43) Cologne, Germany (Ethikkommission der Medizinischen Fakultät der Universität zu Köln: n 17-059) and Barcelona, Spain (Comité Etico de Investigacion Clinica del Hospital Clinic de Barcelona: n HCB/2017/0062). The SCD-Well trial was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵^ Natalie L. Marchant and Antoine Lutz share last authorship
Data Availability
The data underlying this report are made available on request following a formal data sharing agreement and approval by the consortium and executive committee (https://silversantestudy.eu/2020/09/25/data-sharing). The Material can be mobilized, under the conditions and modalities defined in the Medit-Ageing Charter by any research team belonging to an Academic institution, for carrying out a scientific research project relating to the scientific theme of mental health and well-being in older people. The Material may also be mobilized by non-academic third parties, under conditions, in particular financial, which will be established by separate agreement between Inserm and by the said third party. Data sharing policies described in the Medit-Ageing charter are in compliance with our ethics approval and guidelines from our funding body.
